Search results
Results From The WOW.Com Content Network
Stages of metabolic dysfunction–associated steatotic liver disease, progressing from healthy, to steatosis (fat accumulation), inflammation, fibrosis and cirrhosis. Metabolic dysfunction–associated steatotic liver disease ( MASLD ), previously known as non-alcoholic fatty liver disease ( NAFLD ), [ a ] is a type of chronic liver disease.
Show comments. (Reuters) -The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for ...
Key:MRWFZSLZNUJVQW-DEOSSOPVSA-N. Saroglitazar ( INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus, dyslipidemia, NASH and NAFLD It is approved for use in India by the Drug Controller General of India. [1] Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 ...
The drugs were also noted to reduce food intake and body weight significantly, and some have also been approved to treat obesity in the absence of diabetes. They are also in development for other indications, such as non-alcoholic fatty liver disease , polycystic ovary syndrome , and diseases of the reward system such as addictions .
Ivermectin is an antiparasitic drug. [7] After its discovery in 1975, [8] its first uses were in veterinary medicine to prevent and treat heartworm and acariasis. [9] Approved for human use in 1987, [10] it is used to treat infestations including head lice, scabies, river blindness (onchocerciasis), strongyloidiasis, trichuriasis, ascariasis and lymphatic filariasis.
The history of the FDA can be traced to the latter part of the 19th century and the U.S. Department of Agriculture's Division of Chemistry (later Bureau of Chemistry). Under Harvey Washington Wiley, appointed chief chemist in 1883, the Division began conducting research into the adulteration and misbranding of food and drugs on the American market.
Leqembi’s side effects and other potential issues. Leqembi offers doctors the first new Alzheimer’s treatment option in years. But it also has some possibly dangerous side effects. Those ...
Fatty liver disease ( FLD ), also known as hepatic steatosis and steatotic liver disease ( SLD ), is a condition where excess fat builds up in the liver. [1] Often there are no or few symptoms. [1] [2] Occasionally there may be tiredness or pain in the upper right side of the abdomen. [1] Complications may include cirrhosis, liver cancer, and ...